10-Q: Envoy Medical Reports Deepening Losses Amidst Clinical Trial Progress and Going Concern Doubts

Envoy Medical, a hearing health company, reported increased net losses and a growing accumulated deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its Acclaim CI clinical trials.

Summary

• Net loss for the three months ended June 30, 2025, increased to $5.7 million from $3.9 million in the prior year period.
• Net loss for the six months ended June 30, 2025, was $10.7 million, compared to $10.2 million for the same period in 2024.
• Accumulated deficit grew to $297.9 million as of June 30, 2025, from $284.7 million at December 31, 2024.
• Cash balance decreased slightly to $5.3 million as of June 30, 2025, from $5.5 million at December 31, 2024.
• The company received $10.0 million in proceeds from related-party term loans during the six months ended June 30, 2025.
• Research and development expenses increased by $0.3 million to $5.2 million for the six months ended June 30, 2025, primarily due to increased personnel and equipment costs supporting clinical trials.
• General and administrative expenses increased by $0.2 million to $3.9 million for the six months ended June 30, 2025, largely due to a $0.3 million severance accrual for the former CFO.
• Interest expense from related-party term loans significantly increased by $1.0 million to $1.1 million for the six months ended June 30, 2025.
• The company completed implantation for all 10 study participants in the first stage of the Acclaim CI pivotal clinical trial by mid-April 2025, with all devices activated.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting personnel, lack of formal risk assessment, and inadequate controls over significant accounts and IT systems.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including significant and increasing net losses, a large accumulated deficit, and an explicit 'going concern' warning. While clinical progress for Acclaim CI is positive, the financial instability, heavy reliance on related-party debt, and identified material weaknesses in internal controls present substantial risks. The overall sentiment is negative due to the precarious financial position outweighing the developmental milestones.

Positives

• Successfully completed implantation and activation of all 10 study participants in the first stage of the Acclaim CI pivotal clinical trial.
• Received Breakthrough Device Designation from the FDA for the Acclaim CI in 2019, indicating potential for expedited review.
• Net cash used in operating activities improved to $8.2 million for the six months ended June 30, 2025, compared to $10.2 million in the prior year period.
• Successfully raised $0.2 million in net proceeds from an At-The-Market (ATM) offering during Q2 2025.
• Secured $10.0 million in additional term loans from a related party, providing necessary funding for operations.

Negatives

• Incurred a net loss of $5.7 million for the three months ended June 30, 2025, a 38.6% increase from $3.9 million in the same period last year.
• Accumulated deficit reached $297.9 million as of June 30, 2025, indicating significant historical losses.
• Management believes existing cash and future capital raises are sufficient for only one year, raising substantial doubt about the company's ability to continue as a going concern.
• Interest expense from related-party term loans increased by 372.7% for the three months and 566.1% for the six months ended June 30, 2025, due to additional debt issuances.
• General and administrative expenses increased significantly due to a $0.3 million severance accrual for the former CFO.
• Revenue remains nominal, with Esteem FI-AMEI sales not expected to exceed a few per year, if any, due to lack of reimbursement.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to cumulative losses and reliance on future capital raises.
• Unpredictability in the medical device industry, regulatory approval processes, and clinical development timelines for products like Acclaim CI.
• Potential need for design changes to products to meet safety and efficacy endpoints.
• Changes in federal or state reimbursement policies could adversely affect product sales.
• Competition in the medical device industry and the failure to introduce new products in a timely manner or at competitive prices.
• Disruptions in relationships with suppliers or in the company's own production capabilities.
• Changes in the need for capital and the availability of financing on acceptable terms.
• Legal, regulatory, and other proceedings, such as the $9.4 million lawsuit by Atlas Merchant Capital, could be costly and time-consuming.
• Loss of key intellectual property rights or failure to adequately protect them.
• Inability to maintain Nasdaq listing for its securities.
• Effects of catastrophic events, including war, terrorism, and international conflicts, on business and financial performance.
• Adverse macroeconomic conditions, including inflation, rising interest rates, and potential recession, could reduce disposable income and affect product sales and capital access.
• Material weaknesses in internal control over financial reporting, which could lead to material misstatements in financial statements.

Future Outlook

The company expects to continue incurring significant net losses and increasing expenses for the foreseeable future as it advances the clinical development of the Acclaim CI and seeks regulatory approvals. Commercialization expenses are anticipated to increase significantly upon regulatory approval. The company targets FDA approval for the Acclaim CI's Premarket Approval (PMA) application in the second half of 2027 or first half of 2028, depending on the FDA's review process and timeline. There is no guarantee of FDA approval or a specific timeline. The company expects to finance its cash needs through equity offerings, debt financings, or other capital sources, and may need to reduce discretionary spending or delay activities if unable to raise sufficient financing.

Management Comments

• Management believes that existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued.
• Management believes that the lawsuit filed by Atlas Merchant Capital SPAC Fund I LP is meritless and is defending this matter vigorously.
• Management concluded that, as of June 30, 2025, disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• Management believes that the unaudited condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q fairly present in all material respects the financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with U.S. GAAP, despite the material weaknesses.

Industry Context

Envoy Medical operates in the hearing health and medical device industry, focusing on innovative implantable technologies. Its lead product candidate, the Acclaim CI, aims to disrupt the existing cochlear implant market, which already has established market acceptance and reimbursement pathways, unlike its first product, Esteem FI-AMEI. The company's development efforts are subject to the unpredictable regulatory process of the FDA and broader macroeconomic conditions affecting disposable income and access to capital, common challenges for medical device startups in clinical development phases.

Comparison to Industry Standards

• The company's Acclaim CI, a fully implanted cochlear implant leveraging natural ear anatomy instead of a microphone, is described as a 'first-of-its-kind' device, suggesting a unique technological approach compared to existing cochlear implants on the market.
• The Esteem FI-AMEI, the company's first commercial product, is noted as the 'only FDA approved fully implanted hearing device in the US market,' highlighting its unique regulatory status, though it failed commercially due to reimbursement issues.
• The company's financial performance, characterized by significant net losses and a 'going concern' warning, is typical for a medical device company in the late-stage clinical development phase, where substantial R&D investment is required before commercialization and revenue generation.

Management Changes

Corporate Governance

Legal Proceedings

• A complaint was filed on November 14, 2023, by Atlas Merchant Capital SPAC Fund I LP (Atlas) in the Delaware Court of Chancery, naming the company, former CEO Whitney Haring-Smith, former CFO Daniel Hirsch, and Anzu SPAC GP I LLC as defendants.
• Atlas alleges it was not allowed to redeem its shares of the company's Common Stock and seeks approximately $9.4 million in damages, plus interest and fees.
• The company asserts that Atlas did not comply with redemption requirements and believes the lawsuit is meritless, defending the matter vigorously.
• No accruals for potential losses related to this litigation have been recorded as management determined a potential loss is not probable and reasonably estimable.

Related Party Transactions

• The company has outstanding term loans totaling $30.0 million in principal from GAT Funding, LLC, an entity controlled by Glen A. Taylor, a board member and controlling stockholder.
• The company leases its headquarters office space in Minnesota from a company owned by the controlling stockholder, with a lease liability of $0.9 million as of June 30, 2025.
• A shared services arrangement exists with a company indirectly owned by the controlling stockholder for certain support services, with expenses of less than $0.1 million for the three and six months ended June 30, 2025 and 2024.
• The Sponsor (Anzu SPAC GP I LLC, an affiliate of the controlling stockholder) waived $3.7 million of accrued dividends on Series A Preferred Stock in December 2024 in exchange for the removal of vesting restrictions on Contingent Sponsor Shares and a temporary reduction in conversion price.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity offerings and existing warrants. The 'going concern' warning and increasing accumulated deficit pose substantial risk to investment value. The Series A Preferred Stock has cumulative dividends and liquidation preferences senior to common stock.
• **Employees:** Increased R&D personnel costs indicate continued investment in the workforce supporting clinical trials. A severance accrual for the former CFO suggests management changes can impact personnel.
• **Customers/Patients:** Continued development of Acclaim CI offers potential for a new, innovative hearing solution. However, the Esteem FI-AMEI's commercial challenges due to lack of reimbursement highlight potential hurdles for patient access and affordability.
• **Creditors:** The company's reliance on related-party term loans and the 'going concern' warning indicate elevated credit risk, particularly for non-related party creditors if any exist.
• **Suppliers:** Potential disruptions in relationships or production capabilities could affect the supply chain for product components.

Next Steps

• Discuss initial three to six month data on the 10 study participants with the FDA to request expansion into the second stage of the Acclaim CI clinical trial.
• Enroll an additional 46 study participants for a total of 56 patients in the second stage of the Acclaim CI clinical trial (targeting Q4 2025 or Q1 2026).
• Follow each implanted study participant through their 12-month visit.
• Collect and analyze data from all 56 patients after their 12-month visits in accordance with the clinical study protocol and statistical analysis plan.
• Submit a Premarket Approval (PMA) application to the FDA upon finalization of results (anticipated H2 2027 or H1 2028).
• Continue efforts to pursue positive reimbursement changes for fully implanted active middle ear implants (Esteem FI-AMEI).
• Implement a plan to remediate identified material weaknesses in internal control over financial reporting, including hiring additional accounting personnel, designing formal controls, and improving IT general controls.

Key Dates

Recommendation

The company's financial position is highly precarious, evidenced by deepening net losses, a rapidly growing accumulated deficit, and an explicit 'going concern' warning. While clinical progress for the Acclaim CI is noted, the significant financial instability, heavy reliance on related-party debt, and identified material weaknesses in internal controls present overwhelming risks. The company's ability to fund operations beyond the near term is uncertain and contingent on further capital raises, which will likely dilute existing shareholders. For a seasoned investor, the current risk profile far outweighs any speculative upside from future product approval, making a 'strong sell' recommendation appropriate to mitigate potential further losses.

Keywords

Hearing Health, Cochlear Implant, Acclaim CI, Esteem FI-AMEI, Medical Device, FDA Approval, Clinical Trials, Going Concern, SEC Filing, Financial Reporting, Internal Controls, Capital Raise, Nasdaq, Biotechnology